Aurora Cannabis (ACB)
(Delayed Data from NSDQ)
$0.70 USD
0.00 (-0.20%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $0.70 0.00 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.70 USD
0.00 (-0.20%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $0.70 0.00 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 11.11% and 2.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q1 Earnings Match Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 33.33% and 0.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
High Tide Inc. (HITI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 57.14% and 8.29%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 34.15% and 12.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Q1 Earnings Top Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 3.32% and 5.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -147.06% and 4.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis Inc. (ACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $5.50, marking a +0.92% move from the previous day.
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50.00% and -0.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.
Aurora Cannabis Inc. (ACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 0.00% and -2.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aurora Cannabis Inc. (ACB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cannabis Giant Tilray (TLRY) Skyrocketed Today
by Madeleine Johnson
Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.
Aurora Cannabis Inc. (ACB) Stock Jumps 7.7%: Will It Continue to Soar?
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Do Options Traders Know Something About Aurora Cannabis (ACB) Stock We Don't?
by Aditi Saraogi
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Company News for May 17, 2021
by Zacks Equity Research
Companies In The News Are: ACB, NEWR, BLFS, GLOB